First Time Loading...

Myriad Genetics Inc
NASDAQ:MYGN

Watchlist Manager
Myriad Genetics Inc Logo
Myriad Genetics Inc
NASDAQ:MYGN
Watchlist
Price: 21.57 USD 0.79% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. [ Read More ]

The intrinsic value of one MYGN stock under the Base Case scenario is 20.76 USD. Compared to the current market price of 21.57 USD, Myriad Genetics Inc is Overvalued by 4%.

Key Points:
MYGN Intrinsic Value
Base Case
20.76 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Myriad Genetics Inc

Backtest MYGN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MYGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Myriad Genetics Inc's business.

What risks and challenges
does Myriad Genetics Inc face in the near future?

Summarize the latest earnings report
of Myriad Genetics Inc.

Provide P/E
for Myriad Genetics Inc and its competitors.

Financials

Balance Sheet Decomposition
Myriad Genetics Inc

Current Assets 313.6m
Cash & Short-Term Investments 140.9m
Receivables 114.3m
Other Current Assets 58.4m
Non-Current Assets 832.9m
PP&E 180.6m
Intangibles 636.9m
Other Non-Current Assets 15.4m
Current Liabilities 155.9m
Accounts Payable 25.8m
Accrued Liabilities 104.8m
Other Current Liabilities 25.3m
Non-Current Liabilities 207.4m
Long-Term Debt 38.5m
Other Non-Current Liabilities 168.9m
Efficiency

Earnings Waterfall
Myriad Genetics Inc

Revenue
753.2m USD
Cost of Revenue
-236.2m USD
Gross Profit
517m USD
Operating Expenses
-653.9m USD
Operating Income
-136.9m USD
Other Expenses
-126.4m USD
Net Income
-263.3m USD

Free Cash Flow Analysis
Myriad Genetics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MYGN Profitability Score
Profitability Due Diligence

Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
29/100
Profitability
Score

Myriad Genetics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

MYGN Solvency Score
Solvency Due Diligence

Myriad Genetics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
57/100
Solvency
Score

Myriad Genetics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MYGN Price Targets Summary
Myriad Genetics Inc

Wall Street analysts forecast MYGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYGN is 24.85 USD with a low forecast of 12.12 USD and a high forecast of 32.55 USD.

Lowest
Price Target
12.12 USD
44% Downside
Average
Price Target
24.85 USD
15% Upside
Highest
Price Target
32.55 USD
51% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MYGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MYGN Price
Myriad Genetics Inc

1M 1M
0%
6M 6M
+28%
1Y 1Y
-5%
3Y 3Y
-25%
5Y 5Y
-38%
10Y 10Y
-34%
Annual Price Range
21.57
52w Low
13.91
52w High
23.76
Price Metrics
Average Annual Return -13.32%
Standard Deviation of Annual Returns 37.41%
Max Drawdown -79%
Shares Statistics
Market Capitalization 1.9B USD
Shares Outstanding 89 874 896
Percentage of Shares Shorted 6.15%

MYGN Return Decomposition
Main factors of price return

What is price return decomposition?

MYGN News

Other Videos

Company Profile

Myriad Genetics Inc Logo
Myriad Genetics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.9B USD

Dividend Yield

0%

Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,400 full-time employees. The firm primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The firm discovers and commercializes genetic tests. The firm's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company’s wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc., Myriad Women’s Health, Inc, Myriad Genetics Espana SL, Myriad Genetics S.r.l., Myriad Genetics B.V. and Myriad Genetics GK.

Contact

UTAH
Salt Lake City
320 S Wakara Way
+18015843600.0
http://www.myriad.com/

IPO

1995-10-06

Employees

2 400

Officers

CEO, President & Director
Mr. Paul J. Diaz
Chief Technology Officer
Dr. Kevin Richard Haas Ph.D.
Strategic Advisor
Mr. R. Bryan Riggsbee
Chief Commercial Officer
Mr. Mark S. Verratti
Consultant
Ms. Nicole Lambert
Chief Financial Officer
Mr. Scott J. Leffler
Show More
Chief Operating Officer
Mr. Samraat S. Raha
Principal Accounting Officer
Ms. Natalie Munk
Chief Scientific Officer
Dr. Dale Muzzey Ph.D.
Senior Vice President of Investor Relations
Mr. Matthew Scalo
Show Less

See Also

Discover More
What is the Intrinsic Value of one MYGN stock?

The intrinsic value of one MYGN stock under the Base Case scenario is 20.76 USD.

Is MYGN stock undervalued or overvalued?

Compared to the current market price of 21.57 USD, Myriad Genetics Inc is Overvalued by 4%.